Latest & greatest articles for pregnancy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregnancy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregnancy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregnancy

2021. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. (PubMed)

Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. The possibility of preventing pregnancy-induced hypertension (PIH) and pre-eclampsia in primigravidae by suppressing production of thromboxane A2 with low-dose aspirin was investigated in a randomised, placebo-controlled, double-blind trial. 46 normotensive women at 28 weeks' gestation, judged to be at risk of PIH or pre-eclampsia because of an increased blood-pressure response

1986 Lancet

2022. A randomized clinical trial of the insulin pump vs intensive conventional therapy in diabetic pregnancies. (PubMed)

A randomized clinical trial of the insulin pump vs intensive conventional therapy in diabetic pregnancies. Improved perinatal outcome is associated with the prevention of hyperglycemia during pregnancy in diabetic women. To determine whether the method of insulin administration influences the degree of diabetic control obtained, we randomized 22 pregnant diabetic women to intensive conventional insulin therapy (N = 11) and insulin pump therapy (N = 11). Frequent outpatient visits; home glucose

1986 JAMA

2023. The effects of hospital admission for bed rest on the duration of twin pregnancy: a randomised trial. (PubMed)

The effects of hospital admission for bed rest on the duration of twin pregnancy: a randomised trial. 212 women with twin pregnancies were randomly allocated either to receive advice to rest in hospital from 32 weeks' gestation until delivery, or to be part of a control group in which hospital admission was offered selectively (and, on average, 5 weeks later). Preterm delivery was more common among women admitted routinely for bed rest than among controls, and this difference was unlikely

1985 Lancet

2024. Randomised controlled trial of ultrasonographic screening in pregnancy. (PubMed)

Randomised controlled trial of ultrasonographic screening in pregnancy. 510 of 1009 pregnant women in the Trondheim area (Norway) were randomly selected for ultrasound examination at the 19th and 32nd weeks of pregnancy in addition to routine antenatal care. Among the screened women, twins were diagnosed earlier and there were slightly fewer post-term inductions (2.8% versus 4.0%) and fewer low-weight births (2.2% versus 3.6% less than 2500 g), but none of these differences was statistically (...) significant. There were no differences in the condition of the newborn. Small-for-gestational-age births were more often diagnosed antenatally in the screened group and the mothers received more active treatment. During pregnancy, screened women were admitted to hospital more often than unscreened women (15.5% versus 9.2%). The study revealed no adverse short-term biological effects from ultrasound. The cost of the screening programme, including associated costs such as extra hospital admissions

1984 Lancet

2025. The effect of covert bacteriuria in schoolgirls on renal function at 18 years and during pregnancy. (PubMed)

The effect of covert bacteriuria in schoolgirls on renal function at 18 years and during pregnancy. Schoolgirls shown to have covert bacteriuria (CB) by a screening programme and followed up for 5 years to assess whether chemotherapy had any beneficial effect, underwent a further assessment of renal function at the age of 18 years and during subsequent pregnancies. At age 18, glomerular filtration rate (GFR) and urine concentrating ability were the same as in controls, but fractional (...) reabsorption of glucose was significantly reduced in those who had previously been prescribed chemotherapy because of renal scarring or who had been randomly allocated not to receive prophylactic chemotherapy. Those who had had CB as schoolgirls had a higher frequency of CB in pregnancy than did controls, whether or not prophylactic chemotherapy had been given to the subjects when they were schoolgirls. Furthermore, compared with girls who had had such treatment, untreated patients had smaller increments

1984 Lancet

2026. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. (PubMed)

Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Atenolol was compared with placebo in a randomised and double-blind prospective study of 120 women with mild to moderate pregnancy-associated hypertension who were also initially managed conventionally by bed rest. Atenolol given once daily significantly reduced blood-pressure, prevented proteinuria, and reduced the number of hospital admissions. Loss of blood-pressure control leading to withdrawal from

1983 Lancet

2027. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. (PubMed)

Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. 195 (97.5%) children born to hypertensive women participating in a trial of methyldopa treatment during pregnancy were followed from birth and were extensively examined at the age of 7 1/2 years. The frequency of problems with health, physical or mental handicap, sight, hearing, and behaviour was the same in children of treated and untreated women. Sons (...) in pregnancy and is probably preferable to other drugs from the point of view of the neonate and child.

1982 Lancet

2028. Cigarette smoking in pregnancy: Associations with maternal weight gain and fetal growth. (PubMed)

Cigarette smoking in pregnancy: Associations with maternal weight gain and fetal growth. 1159 mother-infant "pairs" have been studied to examine the inter-relationship of cigarette smoking in the latter half of pregnancy, maternal weight gain, and fetal growth. Non-smokers gained significantly more weight than heavy smokers (greater than 15 cigarettes per day) while light-to-moderate smokers (1-14 cigarettes a day) were intermediate. Birth-weight, length, and head circumference of the infants

1976 Lancet

2029. Plasma-urate measurements in predicting fetal death in hypertensive pregnancy. (PubMed)

Plasma-urate measurements in predicting fetal death in hypertensive pregnancy. The relation of perinatal mortality to plasma-urate concentrations and blood-pressure was studied in 332 pregnant patients with hypertension. Perinatal mortality was markedly increased when maternal plasma-urate concentrations were raised, generally in association with severe pre-eclampsia of early onset. Plasma-urate was a better indicator than blood-pressure of prognosis for the fetus. Maternal hypertension, even

1976 Lancet

2030. Fetal outcome in trial of antihypertensive treatment in pregnancy. (PubMed)

Fetal outcome in trial of antihypertensive treatment in pregnancy. 242 women completed a controlled trial of methyldopa ('Aldomet') for moderate hypertension in pregnancy. Active treatment was associated with a significantly improved fetal outcome, due in part to a reduced number of mid-pregnancy abortions. There were 9 pregnancy losses in the control group, which included 4 mid-pregnancy abortions, and 1 fetal loss in the treated group. The birthweight and maturity of viable infants were (...) similar in treated and control groups, and a detailed multivariate analysis confirmed that hypotensive treatment had no effect on fetal growth in utero. The better outcome associated with treatment was not due to the prevention of pre-eclampsia, and may be partly due to a direct or indirect effect of methyldopa on uterine activity. Methyldopa is safe to use for the treatment of hypertension in pregnancy in the context of close medical and obstetric supervision.

1976 Lancet

2031. Prophylactic use of hydrochlorothiazide in pregnancy. (PubMed)

Prophylactic use of hydrochlorothiazide in pregnancy. 5332983 1967 02 10 2016 10 17 0098-7484 198 11 1966 Dec 12 JAMA JAMA Prophylactic use of hydrochlorothiazide in pregnancy. 1150-4 Kraus G W GW Marchese J R JR Yen S S SS eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0J48LPH2TH Hydrochlorothiazide AIM IM Clinical Trials as Topic Female Humans Hydrochlorothiazide adverse effects therapeutic use Hypertension prevention & control Infant (...) Mortality Infant, Newborn Maternal Mortality Obstetric Labor, Premature prevention & control Pre-Eclampsia prevention & control Pregnancy Pregnancy Complications prevention & control 1966 12 12 1966 12 12 0 1 1966 12 12 0 0 ppublish 5332983

1967 JAMA